Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2012
Reporting Period: Second quarter ended June 30, 2012
This filing serves as a notification that the Company issued a press release on August 6, 2012, reporting its financial results for the second quarter of 2012. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references an attached press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes regarding financial performance or operations are detailed in this specific document text. The filing solely announces the issuance of the quarterly results press release.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the attached press release is furnished under Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 6, 2012) for actual Q2 2012 financial figures.
- Verify the Company's cash position and burn rate, as this 8-K does not disclose liquidity details.
- Check for any subsequent filings that may incorporate the press release by reference.
- Confirm the status of the Company's principal executive offices in San Diego, California.